Claims for Patent: 6,800,461
✉ Email this page to a colleague
Summary for Patent: 6,800,461
Title: | Modified factor VIII cDNA |
Abstract: | A modified Factor VIII cDNA is described in which the B-domain of the wild-type Factor VIII cDNA has been deleted and a truncated Factor IX intron 1 has been inserted in one or more locatons of the Factor VIII cDNA. Such modified Factor VIII cDNA may be used for a higher yield production of Factor VIII in vitro as well as in a transfervector for gene therapy. |
Inventor(s): | Negrier; Claude (Irigny, FR), Plantier; Jean Luc (Grigny, FR) |
Assignee: | Aventis Behring GmbH (Marburg, DE) |
Application Number: | 09/880,887 |
Patent Claims: | 1. A process for the production of Factor VIII protein comprising: a) preparing a modified Factor VIII cDNA wherein said Factor VIII cDNA is modified by deletion of the
B-domain encoded sequence and insertion of the truncated Factor IX intron 1 (SEQ ID NO: 9) in one or more splice sites of the Factor VIII cDNA; b) introducing the modified Factor VIII cDNA into a cell; and c) expressing the modified Factor VIII cDNA in
said cell to produce Factor VIII protein.
2. A process for the production of Factor VIII protein comprising: a) preparing a modified Factor VIII cDNA wherein said FaCTOR VIII cDNA is nodified by replacement of the B-domain encoded sequence with nucleotides encoding four arginiines and insertion of the truncated Factor IX intron 1 (SEQ ID NO: 9) in one or more splice of the Factor VIII cDNA; b) introducing the modified Factor VIII cDNA into 2 cell; and c) expressing the modified Factor VIII cDNA in said cell to produce Factor VIII protein. 3. The process as claimed in claim 1, wherein at least one insertion site of the truncated Factor IX intron 1 is chosen from Factor VIII intron 1 splice site, Factor VIII intron 12 splice site, and Factor VIII intron 13 splice site. 4. The process as claimed in claim 2, wherein at least one insertion site of the truncated Factor IX intron 1 is chosed from Factor VIII intron 1 splice site, Factor VIII intron 12 splice site, and Factor VIII intron 13 splice site. |
Details for Patent 6,800,461
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2019-03-17 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2019-03-17 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2019-03-17 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.